USFDA inspections back in full swing for Pharma Companies

USFDA plant inspections seem to be coming back strongly after a two-year hiatus, going by the just-concluded inspection at Zydus Lifesciences on March 10 and a warning letter to Aurobindo earlier this year, in mid-January.

USFDA officials commented in February 2022 that USFDA is keen on restarting pharma companies inspections, including surprise inspections in India.

USFDA could be set for a busy year in India as the backlog of redressals from previous inspections and pending applications for plants and products become pressing.

Earlier, the total number of USFDA plant audits for drug quality assurance in India peaked in 2019 at 239.

Another 80 inspections were completed in January-March 2020 prior to Covid and slid to 5 inspections in 2021.

The surge in audit inspections could be periodic or could also be linked to evolving standards in manufacturing.

Related Posts

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus board approved a buyback of up to Rs 1100 crore at Rs 1,150 per share, along with a 100 percent dividend for FY26. Zydus Lifesciences reported a rise in…

Chemists strike on May 20: Reasons behind today’s all-India strike

While major pharmacy chains and government medical outlets will remain operational, the strike highlights significant tensions within the industry that could impact access to medications nationwide. The All India Organisation…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus Lifesciences Q4FY26 net profit rises 9%

Chemists strike on May 20: Reasons behind today’s all-India strike

Chemists strike on May 20: Reasons behind today’s all-India strike

AbbVie loses patent plea for Hep C drug

AbbVie loses patent plea for Hep C drug

GSK’s Calpol a well-known trademark: High Court

GSK’s Calpol a well-known trademark: High Court

3 arrested for allegedly posing as doctors using forged MBBS degrees

3 arrested for allegedly posing as doctors using forged MBBS degrees

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures